Literature DB >> 20654626

Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine.

Robert D Fisher1, Mark Ultsch, Andreas Lingel, Gabriele Schaefer, Lily Shao, Sara Birtalan, Sachdev S Sidhu, Charles Eigenbrot.   

Abstract

Engineered antibody paratopes with limited sequence diversity permit assessment of the roles played by different amino acid side chains in creating the high-affinity, high-specificity interactions characteristic of antibodies. We describe a paratope raised against the human ErbB family member HER2, using a binary diversity tryptophan/serine library displayed on phage. Fab37 binds to the extracellular domain of HER2 with sub-nanomolar affinity. An X-ray structure at 3.2 A resolution reveals a contact paratope composed almost entirely of tryptophan and serine residues. Mutagenesis experiments reveal which of these side chains are more important for direct antigen interactions and which are more important for conformational flexibility. The crystal lattice contains an unprecedented trimeric arrangement of HER2 closely related to previously observed homodimers of the related epidermal growth factor receptor. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20654626     DOI: 10.1016/j.jmb.2010.07.027

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  19 in total

1.  Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.

Authors:  Sashikanth Banappagari; Miriam Corti; Seth Pincus; Seetharama Satyanarayanajois
Journal:  J Biomol Struct Dyn       Date:  2012-06-26

2.  Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions.

Authors:  Christian Jost; Jakob C Stüber; Annemarie Honegger; Yufan Wu; Alexander Batyuk; Andreas Plückthun
Journal:  Protein Sci       Date:  2017-07-05       Impact factor: 6.725

3.  Optimization of peptidic HIV-1 fusion inhibitor T20 by phage display.

Authors:  Gang Chen; Jonathan D Cook; Wei Ye; Jeffrey E Lee; Sachdev S Sidhu
Journal:  Protein Sci       Date:  2019-08       Impact factor: 6.725

4.  Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.

Authors:  Karim Salazar-Salinas; Carlos Kubli-Garfias; Jorge M Seminario
Journal:  J Mol Model       Date:  2012-11-10       Impact factor: 1.810

5.  Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells.

Authors:  Sandeep Pallerla; Ted Gauthier; Rushikesh Sable; Seetharama D Jois
Journal:  Eur J Med Chem       Date:  2016-10-10       Impact factor: 6.514

Review 6.  Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors.

Authors:  Shanthi Kanthala; Sandeep Pallerla; Seetharama Jois
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

7.  Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells.

Authors:  Shanthi Kanthala; Christopher P Mill; David J Riese; Mihir Jaiswal; Seetharama Jois
Journal:  Protein Expr Purif       Date:  2015-09-09       Impact factor: 1.650

8.  Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.

Authors:  Shanthi Kanthala; Ted Gauthier; Seetharama Satyanarayanajois
Journal:  Biopolymers       Date:  2014-06       Impact factor: 2.505

9.  Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.

Authors:  Wenyan Fu; Yuxiao Wang; Yunshan Zhang; Lijuan Xiong; Hiroaki Takeda; Li Ding; Qunfang Xu; Lidong He; Wenlong Tan; Augus N Bethune; Lijun Zhou
Journal:  MAbs       Date:  2014-04-16       Impact factor: 5.857

10.  Structural and dynamic characterization of the C-terminal tail of ErbB2: Disordered but not random.

Authors:  Louise Pinet; Ying-Hui Wang; Célia Deville; Ewen Lescop; Françoise Guerlesquin; Ali Badache; François Bontems; Nelly Morellet; Dominique Durand; Nadine Assrir; Carine van Heijenoort
Journal:  Biophys J       Date:  2021-03-17       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.